Novo Nordisk A/s

This study tests a once-weekly injection called CagriSema (cagrilintide plus semaglutide) in 80 children and teens with type 2 diabetes. The goal is to see if it lowers blood sugar and body weight better than a placebo. The study lasts about 1 year and 3 months, with all particip…

This study will monitor about 600 adults with type 2 diabetes who are starting Rybelsus as part of their normal care. The goal is to track any side effects and how well the medicine controls blood sugar over 26 weeks. Participants take the pill as prescribed by their doctor, with…

This study tests a new medicine called CagriSema to see how well it helps people with obesity lose weight, compared to an existing drug, semaglutide. About 2500 adults with a BMI of 35 or higher, with or without type 2 diabetes, will take part. The trial lasts 83 weeks and measur…

This study tests a new medicine, NNC0487-0111, given as a weekly injection, in about 5,600 people who have both heart failure and obesity. The goal is to see if it can reduce the risk of death or hospitalization compared to a placebo. Participants will be randomly assigned to rec…

This study tests a new weekly injection, NNC0487-0111, against the approved drug semaglutide in 1000 adults with overweight or obesity and type 2 diabetes. Participants will receive two weekly shots (one active, one placebo) for about a year. The main goal is to see how much weig…

This study tests an experimental medicine, CagriSema, to see how well it lowers blood sugar in people with type 2 diabetes. About 400 adults aged 18-64 with stable diabetes will receive one of two versions of the drug, given by different injection devices. The study lasts about 3…

This study tests a new medicine called NNC0662-0419 for people with type 2 diabetes. About 270 adults will receive either the new drug, an approved drug (semaglutide), or a placebo as a weekly injection. The goal is to see if the new drug safely lowers blood sugar and helps with …